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Avocado/soybean unsaponiﬁables, ASU EXPANSCIENCE, are strictly
different from the nutraceutical products claiming ASU appellationLaboratoires EXPANSCIENCE have discovered, devel-
oped and produced a pharmaceutical product, PIASCLE-
DINE 300, which is effective for the ‘‘symptomatic,
delayed-effect treatment of arthrosis of the hip and knee’’
(wording from the MA indication). The active principle of
this pharmaceutical product is called ASU EXPAN-
SCIENCE and is composed of a mixture of soybean
unsaponiﬁables and speciﬁc avocado unsaponiﬁables.
The speciﬁcities of the product and elements of the process
are protected by patents.
Recently, Au RY et al. have demonstrated that a so called
ASU extract, named ASU-NMX 1000TM (Nutramax Labora-
tories Inc, Edgewood, MD, USA), suppressed tumour ne-
crosis factor (TNF)-a, IL-1b, cyclooxygenase (COX)-2 and
iNOS gene expression, and PGE2 and nitric oxide produc-
tion in articular chondrocytes and monocyte/macrophages1.
In the introduction, following a brief point on arthrosis, the
mediators involved and the usual treatments (NSAIDs)
prescribed for treating this pathology, the authors propose
the use of avocado and soybean unsaponiﬁables (ASU)
as an alternative or additional therapeutic approach. To
make their case, the authors list and describe several
clinical, animal and in vitro studies demonstrating the phar-
macological and clinical efﬁcacy of ASU.
We must draw your attention to the fact that the ASU
used and tested in all of the studies referred to in the text
are strictly original and unique ASU EXPANSCIENCE e
active ingredient of the patented pharmaceutical product
PIASCLEDINE 300 from Laboratoires EXPANSCIENCE
and there is no existing alternative on the market. For
many years, mainly in Europe but also in other parts of
the world, the action of ASU EXPANSCIENCE in the
symptomatic treatment of arthrosis has been recognised
through the pioneering, original investment of Laboratoires
EXPANSCIENCE.
In the following sections of the text, the authors describe
and discuss in vitro studies aiming to demonstrate the
biological activity of ASU-NMX1000 (NUTRAMAX Labora-
tories), which have nothing in common structurally with
ASU EXPANSCIENCE, except for the general label
ASU.
As such, scientiﬁcally speaking, these results cannot
under any circumstances be put into perspective or
combined with the data that have been published by our*Address correspondence and reprint requests to: C. Baudouin,
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on ASU EXPANSCIENCE for nearly 20 years2e10.
To give the scientiﬁc community appropriate clariﬁcation
on these structural differences, we can say that ‘‘the
originality of PIASCLEDINE 300 is based on the A/S ratio
(1:2) and speciﬁc composition of both unsaponiﬁables. The
main components of these unsaponiﬁables are tocopherols,
sterols and speciﬁc molecules from avocado obtained by
proprietary and particular patented process’’11e13. Such
avocado unsaponiﬁable (AU) is quite different from com-
mon, natural AU. The active substance, ASU EXPAN-
SCIENCE, is obtained in the pharmaceutical quality
context by controlling all in-process steps and the traceabil-
ity of the entire production chain.
We have also studied three NUTRAMAX commercial
products containing ASU-NMX 100:
 DASUQUIN with MSM;
 DASUQUIN; and
 AVOCA ASU,
in comparison with our ASU EXPANSCIENCE. The
results of the study were presented at the poster session
of the last OARSI World Congress on Osteoarthritis 2007
in Fort Lauderdale14.
In order to characterise each product chemically, we have
used different analytical methods that have been validated
according to ICH Q2R1 guidelines:
gas chromatography;
UV spectrometry;
unsaponiﬁable content determined by ‘‘the American Oil
Chemistry Society N Ca 6a-40’’ method; and
a mathematical approach to the analytical data has
been performed by Normalised Principal Component
Analysis (nPCA)14.
The analysis of data signiﬁcantly demonstrated that the
commercial nutraceutical products from NUTRAMAX claim-
ing the ASU label are totally different from the common and
natural sterol based avocado and soybean unsaponiﬁables
and also from ASU EXPANSCIENCE (PIASCLEDINE
300) (Tables I and II):
1. Absence of or no detectable speciﬁc molecules from
common natural avocado unsaponiﬁables like the
key molecule, citrostadienol;
2. Absence of patented molecules from Laboratoires
EXPANSCIENCE;
Table I
Content of each fraction evaluated by chromatographic analyses
Content in %w/w EXPANSCIENCE
patented molecules
Tocopherols
(alpha-tocopherol,
delta-tocopherol,
gamma-
tocopherol)
Sterols
(brassicasterol,
campesterol,
stigmasterol,
beta-sitosterol,
citrostadienol)
Proportion of
brassicasterol*
in the phytosterols
pool
Proportion of
citrostadienoly
in the phytosterols
pool
ASU EXPANSCIENCE >10 >10 >15 Not detected Presence
DASUQUIN with MSM e
NUTRAMAX
(DASU MSM NUTR)
Not detected 0.1 28.2 1.4% Not detected
DASUQUIN e NUTRAMAX
(DASU NUTR)
Not detected 0.5 30.0 1.3% Not detected
AVOCA ASU e NUTRAMAX
(AVOCA ASU NUTR)
Not detected 1.0 49.9 1.4% Not detected
*Rapeseed oil or related unsaponiﬁables imprint.
yAvocado unsaponiﬁable imprint.
Table II
Analysis of the differences in composition
ASU
EXPANSCIENCE
(PIASCLEDINE 300)
NUTRAMAX
commercial
nutraceutical products
Patented
molecules
Yes No
Tocopherols Yes Yes but divided by 25e50
Sterols
From
soybean
Yes Yes
From
avocado
Yes No (citrostadienol
absent or non detectable)
From
rapeseed
No Yes ( presence of
brassicasterol)
ASU as
conclusion
Yes 100% No (NUTRAMAX
commercial nutraceutical
products presented as
unsaponiﬁables are mainly
composed of soybean and
rapeseed sterols)
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rapeseed oil and related unsaponiﬁables;
4. Very low tocopherols content: it demonstrates that the
compositions of NUTRAMAX commercial nutraceuti-
cal products do not correspond to real soybean oil
unsaponiﬁables; and
5. The speciﬁc proportion of ASU EXPANSCIENCE
(1:2) is not maintained.
In conclusion, we would like to remind scientists and
rheumatologists of the risk of confusion arising from the
commercial or scientiﬁc use of the acronym ASU with no
chemical basis, the unauthorised use of scientiﬁc property,
and the abused backing of ASU EXPANSCIENCE
(PIASCLEDINE 300). The speciﬁc composition of ASU
EXPANSCIENCE (PIASCLEDINE 300) is associated
with the widely demonstrated in vitro and in vivo clinical
activities allowing the recommendation of the original,
authentic and pharmaceutical ASU EXPANSCIENCE in
the management of osteoarthritis2e10,15.P. Msika, Ph.D., C. Baudouin, Ph.D.*,
A. Saunois, Ph.D., T. Bauer, Ph.D.
Laboratoires EXPANSCIENCE, R&D Center,
Rue des quatre filles BP 25034,
28231 Epernon Cedex, FranceReferences
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